37 results about "Ellagitannin" patented technology

The invention relates to a method of using pomegranate rind as raw material to prepare ellagic acid by enzymatic method, belonging to the food, medical and chemical fields. The method uses the pomegranate rinds which are numerously discarded by people in China as raw materials to extract ellagitannin. The characteristics of high catalysis efficiency, strong selectivity, moderate processing conditions, and the like of enzyme are used to obtain tannase containing degraded ellagitannin through fermentation. The enzymatic reaction between the tannase and the ellagitannin happens to generate the ellagic acid. After the solvent crystallization purification, the medical ellagic acid with dear price and high purity is obtained. The method can lower the cost of the raw material, reuse wastes, improve the yield and the purity of the ellagic acid and can be applied to the large scale production.

The present invention discloses an extraction method of sweet tea active ingredients, the steps are as follows: 1) sweet tea leaves are placed into the water and the complex enzyme is used for enzyme hydrolysis; 2) the enzymatic inactivation and filtration are carried out for the obtained enzymatic hydrolysate to get the filtrate; 3) the separation is carried out for filtrate to get the ellagitannin and the separation liquid; 4) the absorption and separation are carried out for the separation liquid by using the anion exchange resin, then the anion exchange resin is eluted and the solvent used for elution is recovered and dried to get the gallic acid; 5) the liquid is flowed out after the absorption and separation of the separation liquid by the anion exchange resin, the liquid is treated with absorption and separation by macroporous absorption , then the macroporous absorption resin eluted, the solvent used for elution is recovered and dried to get the rubusoside. The extraction method of sweet tea active ingredients of the present invention can separate the ellagitannin, gallic acid, rubusoside and other active ingredients in the sweet tea leaves sequentially. The extraction method has simple operation and can lower the energy consumption, improve the comprehensive utilization rate of the sweet tea and provide the raw materials and intermediates for the health care drugs.

The invention discloses a method for extracting ellagic acid in pomegranate peel residue by using biological enzyme, belonging to the fields of food, medicine and chemical engineering. The method takes the pomegranate peel residue as raw material and water as solvent, and can be used for preparing the ellagic acid by using the biological enzyme. Biological compound enzyme of degradable ellagitannin can be used for carrying out enzymolysis reaction on the ellagitannin, and alkaline liquor is used for stopping the enzymolysis reaction; simultaneously, an alkaline water system can be formed for extracting the ellagic acid, and crude product of the ellagic acid can be obtained; and the extraction rate of the ellagic acid reaches 12.69-24% based on the content of the ellagitannin obtained in the step (1). The method has simple and continuous technique, environment-friendly manufacturing process, environmental protection and less discharge of the three wastes, and is suitable for large-scale industrialized production.

The invention relates to a circulating cooling water corrosion and scale inhibitor and a preparation method thereof. The circulating cooling water corrosion and scale inhibitor is composed of polyacrylamide, sodium gluconate, amino trimethylene phosphonic acid, ammonium molybdate, cyclohexylamine, a surface active agent, a plant extract, a preservative and water, wherein the plant extract is composed of gallic acid, chlorogenic acid, gallotannin and ellagitannin. Therefore, the circulating cooling water corrosion and scale inhibitor is applicable to recycling of an industrial circulating cooling water system and high-concentration-multiple and corrosive water, and anticorrosion, antiscale and low discharge effects of high salinity wastewater in circulating cooling water are realized.

A means and method for increasing or inhibiting the secretion of cytokines using gallotannins and ellagitannins is described. The preferred cytokine release inhibiting compounds are dimeric gallotannins having a linker molecule that misaligns the carbohydrate cores of the compounds. The preferred cytokine release promoting gallotannins and ellagitannins include a diaryl ether linker unit. In comparison to the more structurally complex ellagitannins, the compounds of this invention are structurally simpler, easier to synthesize, and more potent.

The present invention relates to pharmaceutical, therapeutic, and dietary compositions derived from leaf of the Lagerstroemia speciosa L. plant and the novel extraction processes used to produce these controlled blends of varying composition with respect to corosolic acid, gallotannins, ellagitannins, and valoneic acid dilactone. Embodiments of the invention include an approximately 15.5% to about 98.5% mixture of a corosolic acid rich banaba leaf extract in a tannic acid enriched base for novel combinations for pharmaceutical, therapeutic and/or dietary compositions that yield healthful benefits. Some embodiments of the invention do not include corosolic acid, or include it at a low concentration in combination particularly enriched in other compounds. Such extract compositions that do not contain corosolic acid, are the product of extraction process that yield controllably increased ratios of gallotannins, ellagitannins, and valoneic acid dilactone. Such compositions, both those containing corosolic acid and those lacking corosolic acid are efficacious in effecting control of blood glucose levels, and can be further enhanced in their efficacy by post production and formulation strategies that utilize nanotechnological approaches, targeted deliver enteric coatings, and specialized microenacapsulations. With respect to the individual compounds of these extract compositions, such compounds show combined effects that are both additive and synergistic regarding improved glucose cellular uptake, reduction in blood glucose, insulin efficiency and the simultaneous reduction in assimilation of sugars and starches, and weight loss. Further, additive and synergistic effects are a potential benefit when these compositions are combined with other second therapeutic agents.

A fructose absorption inhibitor according to the present invention comprises a hydrolyzable tannin as an active ingredient. The hydrolyzable tannin preferably has a form composed of a gallic acid derivative and/or an ellagic acid derivative bound to a hydroxy group in glucose via an ester bond, and includes ellagitannin, gallotannin and so on.

The invention discloses a raspberry compound and its preparation method, wherein the raspberry compound is a mixture prepared by respective extraction and mixing of raspberry leaf, centella asiatica, dandelion and honeysuckle; the preparation method comprises respective extraction of the raspberry leaf, centella asiatica, dandelion and honeysuckle by a biological extraction technology to form extracts, and mixing of the extracts of the raw materials to form the raspberry compound. The raspberry compound is prepared as follows: using raspberry as a main raw material, matching the centella asiatica, dandelion and honeysuckle, respectively separating and concentrating into thick paste, and evenly mixing, so that antioxidant, anti-allergy and itching relieve effects of ellagitannic acid in the raspberry can be combined with antibacterial and tissue regeneration promoting effects of asiaticoside, broad-spectrum antibacterial and anti-inflammatory effects of the dandelion and honeysuckle can be assisted, and the raspberry compound can be widely used as raw materials of cosmetics, skin care products, food, health products, medicines, topical antibacterial bacteriostatic agents and other products.

A means and method for increasing or inhibiting the secretion of cytokines using gallotannins and ellagitannins is described. The preferred cytokine release inhibiting compounds are dimeric gallotannins having a linker molecule that misaligns the carbohydrate cores of the compounds. The preferred cytokine release promoting gallotannins and ellagitannins include a diaryl ether linker unit. In comparison to the more structurally complex ellagitannins, the compounds of this invention are structurally simpler, easier to synthesize, and more potent.

The invention discloses a novel ellagic tannins alpha-glucosidase inhibitor and a preparation method thereof. The method comprises the following steps: (1), crushing an immature rubus chingii hu fruit, using ethyl alcohol with certain concentration for reflux extraction, and performing filtering to obtain a rubus chingii hu extraction solution; (2), performing concentration on the extraction solution, adding deionized water to prepare a suspension, using n-butanol for extraction, and obtaining a n-butanol extract; (3), performing concentration on the n-butanol extract to concrete, after redissolving the concrete in the deionized water, adding a product to a macroporous resin column, using the ethyl alcohol for elution, and obtaining an ethyl alcohol eluent; (4), after the concentration ofthe ethyl alcohol eluent, redissolving a product in methyl alcohol, adding the product to an OSD column, using methyl alcohol for elution, collecting the eluent, performing concentration, and obtaining a methyl alcohol concentrated solution; and (5), adjusting the methyl alcohol concentrated solution to suitable concentration, adopting PHPLC (preparative high performance liquid chromatography) topreparation, and obtaining the new ellagic tannins alpha-glucosidase inhibitor. The new ellagic tannins alpha-glucosidase inhibitor is an ellagic tannins compound, which is isolated and identified forthe first time. Compared with common alpha-glucosidase inhibitor hypoglycemic drug-acarbose, the new ellagic tannins alpha-glucosidase inhibitor has significant higher inhibitory activity on alpha-glucosidase, and has great value in drug development.

A cat or dog food bar containing ellagitannin compounds to reduce or prevent a dog or cat's chance of developing a benign or malignant tumor.

An anticancer agent containing ellagitannin, a combination use anticancer agent wherein the anticancer agent and an anticancer agent containing anthracyclines are used in combination.

The invention belongs to the field of biological medicine and particularly relates to an application of ellagitannins flavone in preparation of antitumor drugs. The structural formula of the ellagitannins flavone Thonningianins A is shown by formula I; the Thonningianins A can effectively inhibit the proliferation of tumor cells and significantly promote cell apoptosis so as to result in death of the tumor cell, moreover, the dosage of the Thonningianins A is low, the toxic or side effect is lower than that of common chemotherapeutics on clinic, the route of administration is simple and the operation is easy.

The present invention provides lipase inhibitory agents comprising a gallotannin or ellagitannin component(s) isolated from teas or Tellima grandiflora as well as foods and beverages and medicines containing said inhibitory agents.

The present invention provides lipase inhibitory agents comprising at least one of compounds represented by formula I below:

wherein R₁, R₂ and R₃ independently represent H or a gallic acid residue, and R₄ and R₅ represent H or a gallic acid residue, or R₄ and R₅ together form an HHDP group represented by the formula below:

provided that at least two of R₁ to R₅ represent a gallic acid residue or when all of R₁, R₂ and R₃ are H, R₄ and R₅ together form the HHDP group; as well as foods and beverages and medicines containing said lipase inhibitory agents.

The invention discloses a method of extracting and separating a triterpenoid ellagitannin compound from castanopsis fissa leaves. The method comprises following steps of: 1) extracting the castanopsis fissa leaves used as a raw material by using acetone to obtain an extract; 2) recovering the acetone in the extract and filtering to obtain a filtrate; 3) passing the filtrate through macroporous resin, washing with water, eluting by using 20-50% in volume of an organic solvent, then eluting by using 70-100% in volume of the organic solvent until the eluate has no reactions of phenols, and collecting the eluate of 70-100% in volume of the organic solvent; and 4) recovering the solvent in the eluate under reduced pressure until a large quantity of crystals precipitate, cooling, permitting the eluate to stand and separating the crystals. According to the method, the macroporous resin is used for chromatography and the special eluting technology is combined, and therefore the cost is reduced, the product yield which can reach over 0.37% is improved at the same time, and the purity is high. The method is simple in operation and prone to industrialization.

Methods for building muscle tissue in a subject are described, which comprise administering an ellagitannin compound represented by the following formula (I) to a subject in need thereof:

The ellagitannin compound represented by the formula (I) may be casuarinin or stachyurin, and is administered in a therapeutically effective amount. For instance, the ellagitannin compound may be administered in an amount effective for activating muscle satellite cells. These methods increase and/or maintain muscle mass, as well as prevent and/or suppress a decrease of muscle mass and/or a decrease of muscle force. In certain embodiments, the subject is a human, such as an elderly person. In particular these methods are useful for subjects having or at risk of diseases such as sarcopenia, locomotive syndrome and/or frailty. The ellagitannin compound represented by the formula (I) may be administered as a component of a food or drink composition.